NBIX Shorts Caught Out as Stock Posts 13% Earnings Pop

Neurocrine Biosciences delivered its biggest single-day gain in recent memory on November 3, jumping 13.4% to $164.85 after Q3 results, leaving a rebuilt short position badly offside.

Short interest had climbed steadily through October, rising 25% over the month to reach 6.56 million shares, equal to 6.6% of the free float. That was the highest level in at least a year, a sustained build documented in the previous ORTEX earnings preview note. The position has barely moved on the week, up just 0.3%, which means most of those shorts held through the print rather than covering into it. Borrow conditions offer them no urgency: availability remains extremely loose at nearly 1,991%, meaning shares to lend outnumber existing short positions by roughly 20 to one. Cost to borrow has also eased, falling 14% over the past week to 0.36%, a multi-month low. There is no mechanical squeeze pressure in the lending market; shorts can stay.

Options positioning shifted modestly in the days after the result. The put/call ratio edged up to 0.52, slightly above its 20-day average of 0.50 and sitting at a z-score of 1.37. That is a mild tilt toward caution, not an extreme reading. The 52-week high of 1.76 on the PCR puts the current level well inside normal territory. The short score has also been drifting higher, reaching 45.8 on November 3 from 42.8 two weeks earlier, a gradual signal rather than a sharp warning.

Analysts responded to the Q3 print with broad target increases, though conviction remains split. Guggenheim raised its target to $224 while maintaining Buy, and Canaccord and Piper Sandler both lifted targets into the $210 to $220 range. RBC Capital moved to $190 and Morgan Stanley edged its target to $185, keeping an Equal-Weight rating. The mean target now sits at $207, implying roughly 26% upside from the current price. The bull case rests on Ingrezza's record new-patient additions, Crenessity's strong launch trajectory with Q3 sales expected near $210 million, and a funded pipeline with multiple late-stage readouts through 2027. Bears point to IRA pricing pressure arriving in 2029, which they estimate will cut gross-to-net deductions on Ingrezza to 28.7% from 19.6%, and to competitive risk around Crenessity from atumelnant. On valuation, the trailing PE has expanded to 14.1 times and EV/EBITDA to 11.6 times, both up meaningfully from a month ago as the share price ran ahead of estimate revisions.

Wikipedia attention has spiked alongside the earnings move. ORTEX Alt Data puts retail attention at a z-score of 2.6 relative to the prior 90 days, a two-and-a-half standard deviation reading as of October 22, before the Q3 print arrived. No datasets for Neurocrine have a measured lead against its reported financials, so the attention signal is colour rather than a leading indicator of revenues or earnings.

The MSCI November quarterly review adds a mechanical dimension worth tracking. ORTEX puts a 27% chance on NBIX joining both MSCI World Small and MSCI USA Small in the November review, which would require an estimated $1.2 billion of index-tracker buying equivalent to 5.7 days of normal volume. Simultaneously, ORTEX puts a 28% chance on deletion from MSCI World, MSCI USA, MSCI Kokusai and MSCI North America. The price that decides the deletion is $177.31: NBIX is currently 7.6% below that level. The announcement date is November 11, with the trade date November 30 and effective December 1. Neither outcome is confirmed; ORTEX's forecasts are probabilities, not announcements.

Director George Morrow sold roughly 6,700 shares on November 3 across multiple tranches at prices between $158 and $169, all under a pre-arranged 10b5-1 plan. The sales are mechanical rather than discretionary, and the significance score assigned to each transaction is low. The 90-day net insider position is minus $3.2 million in value and minus 20,291 shares, almost entirely from planned sales of this type.

The stock outran its peers sharply this week. EXEL rose 10.7% and PTCT gained 9.7%, both solid results but behind NBIX's 12.9%. GNLX fell 6.3% and GLUE slipped 2.3% over the same period, suggesting the broader mid-cap biotech group was mixed while NBIX moved decisively on its own catalyst.

The key date to watch next is November 11, when MSCI announces the results of the quarterly review, a decision that will clarify whether the stock faces index-driven selling or buying pressure heading into month-end.